The world questions the vaccines applied in Argentina – economic, financial and economic news

The Brazilian National Health Surveillance Agency (Anvisa) has not authorized the importation of Sputnik V – requested by 14 states – by the “Lack of consistent and reliable data” on the vaccine.

According to the entity, vaccine development failures have been identified in all phases (1, 2 and 3) of clinical trials, and data on quality control, safety and efficacy are lacking.

“One of the critical points (…) is that the cells where the adenoviruses are produced for the development of the vaccine allow their replication. This can lead to infections in humans, and can cause damage and death, especially in people with blood pressure, immunity and respiratory problems, among other health problems, ”the official statement explained.

The Gamaleya Institute and the Russian Direct Investment Fund (DRIF) dismissed the Brazilian agency’s questions. The DRIF attributed the decision to a political issue and to the American lobby.

Although the vaccine is applied in 62 countries, including Argentina, Not yet approved by the Food and Drug Administration (FDA) or the European Medicines Agency (EMA), two of the world’s leading health agencies.

The EMA is conducting a “continuous review” of the vaccine. This is the first step in the emergency clearance application process, although it does not mean that it will be approved.

So far, the United States has only approved vaccines from Pfizer-BioNTech, Moderna and Johnson & Johnson, while Europe has also approved that from Oxford-AstraZeneca.

So far, Hungary and Slovakia are the only two countries in the European Union (EU) to have approved the vaccine. Recently, however, Slovakia decided to advise against its application, the regulator assured that the vaccine delivered to the country was different from Sputnik V, whose results had been published in The Lancet, with an effectiveness of 91%. According to the Russians, it was an act of sabotage and a campaign of disinformation.

Germany has also expressed interest in acquiring the vaccine, if it is approved by the EMA.

Chinese vaccines – including Sinopharm, which is also applied in Argentina – have also not been approved by the FDA or EMA, although the CanSino and Sinovac vaccines received advice from the European body.

Regionally, Sinopharm has so far been approved in Peru, Bolivia, Guyana and Venezuela. It also applies in more than 35 countries, including Hungary, the only country in the EU.

Vaccines are back at the center of the debate as the “Covid passport” passes, begins to reopen their borders.

Europe has started work on a digital green certificate to facilitate the free movement of tourists, overlooking the summer season. The idea is that those who have the certificate and therefore can prove that they are vaccinated, have a negative PCR test or have recovered from the disease, can travel to the EU without restrictions or quarantines.

Although this is not a condition to enter the block, countries are only required to accept EMA approved vaccine certificates, a point that could possibly leave out those vaccinated with Sputnik V or Chinese vaccines, among others.

Something similar is happening with China. Although the country has closed its borders for more than a year, it has recently started making entry more flexible for travelers from some 23 countries. With only one condition: to have received two doses of one of the Chinese vaccines which, however, are not available in many Western countries.

Last week, however, the Chinese Embassy in the United States announced that it would expand the admission of Americans who have been vaccinated with Pfizer, Modera, or J&J. In turn, the United States will allow the entry of Chinese students, as it has done before with the Europeans.